WuXi AppTec's Recognition as a Leader in CRDMO Services
WuXi AppTec, a prominent global company specializing in research and development, has been distinguished as the Global CRDMO Company of the Year by Frost & Sullivan for the eighth consecutive time. This remarkable achievement reaffirms the company's ongoing commitment to delivering exceptional services within the pharmaceutical and life sciences industries.
Commitment to Quality and Innovation
WuXi AppTec's recognition highlights its steadfast dedication to meeting the diverse needs of its clients through its innovative contract research, development, and manufacturing organization model. From the initial phases of drug discovery to final commercialization, the company's CRDMO model ensures unparalleled quality standards and comprehensive support throughout the entire drug development process.
Enhancing Customer Experience
Dr. Ge Li, Chairman and CEO of WuXi AppTec, expressed pride in receiving this esteemed award, emphasizing the company's mission to strengthen its integrated CRDMO business model. This model is designed to enhance collaboration and spur innovation, enabling clients to deliver advanced treatments to patients globally.
Leadership in the Industry
Ojaswi Rana, a research analyst, shared that WuXi AppTec's proactive methodology in addressing the evolving demands of the pharmaceutical and biotech sectors showcases the firm's significant contributions to scientific advancements. By continuously upgrading its capabilities, the company effectively supports its clients in bringing innovative therapies to those in need.
Supporting Groundbreaking Therapies
Frost & Sullivan reserves its accolades for companies that push the envelope in innovation and industry growth. By consistently developing new products and solutions, WuXi AppTec stands at the forefront of meeting changing customer demands, illustrating its commitment to industry progress.
About WuXi AppTec
Operating on a global scale, WuXi AppTec has established an extensive portfolio of R&D and manufacturing services that empower the pharmaceutical and life sciences industry to achieve remarkable discoveries. The company's end-to-end solutions encompass a variety of services, including chemistry drug CRDMO, biology discovery, and advanced therapies CTDMO, which enhance customer productivity and streamline healthcare product development.
With an impressive AA ESG rating from MSCI for the fourth consecutive year, WuXi AppTec's open-access platform serves over 6,000 customers across more than 30 countries, reinforcing its vision that "every drug can be made and every disease can be treated." The organization's dedication to improving global health is evident through its comprehensive service offerings and industry leadership.
Frequently Asked Questions
What is WuXi AppTec known for?
WuXi AppTec is known for its comprehensive portfolio of R&D and manufacturing services that support the pharmaceutical and life sciences industries.
How many times has WuXi AppTec received the Global CRDMO Company of the Year Award?
WuXi AppTec has received the Global CRDMO Company of the Year Award for eight consecutive years.
Who is the CEO of WuXi AppTec?
The CEO of WuXi AppTec is Dr. Ge Li, who is committed to driving innovation and enhancing customer collaboration.
What are the services provided by WuXi AppTec?
WuXi AppTec offers a range of services including contract research, development, and manufacturing, as well as advanced therapies and preclinical testing.
Where does WuXi AppTec operate?
WuXi AppTec operates globally with a presence in Asia, Europe, and North America, serving clients from over 30 countries.
